|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Product sales, net | |||||
| Licensing revenue | |||||
| Net revenues | |||||
| PEDMARK | |||||
| Total net revenues | |||||
| Cost of products sold | |||||
| Gross profit | |||||
| Operating expenses: | |||||
| Cost of product sales | |||||
| Research and development | |||||
| Selling and marketing | |||||
| General and administrative | |||||
| Total operating expenses | |||||
| (Loss)/income from operations | |||||
| Other income/(expense) | |||||
| Unrealized foreign exchange gain/(loss) | |||||
| Amortization expense | |||||
| Unrealized loss on securities | |||||
| Loss on debt extinguishment | |||||
| Interest income | |||||
| Interest expense | |||||
| Total other expense | |||||
| Loss before income tax | |||||
| Income tax | |||||
| Net loss | |||||
| Basic net loss per common share | |||||
| Diluted net loss per common share | |||||
| Weighted-average number of common shares outstanding basic | |||||
| Weighted-average number of common shares outstanding diluted | |||||
Loading...